2-methoxyestradiol inhibits melanoma cell growth by activating adaptive immunity

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Melanoma patient survival remains poor despite current treatments, necessitating novel therapeutic strategies.
• 2-methoxyestradiol (2-ME), an estrogen metabolite, exhibits anti-tumor properties, but its role in melanoma is not well-defined.
• Investigating 2-ME's efficacy and mechanisms in melanoma is crucial for developing new treatments.

Purpose of the Study:

• To evaluate the anti-tumor effects of 2-methoxyestradiol (2-ME) on melanoma cells in vitro and in vivo.
• To elucidate the mechanisms underlying 2-ME's action on melanoma proliferation, migration, apoptosis, and cell cycle.
• To assess the potential of 2-ME as a synergistic agent in combination with PD-1 blockade therapy for melanoma.

Main Methods:

• In vitro studies involved treating B16 melanoma cells with 2-ME to assess proliferation, migration, apoptosis, and cell cycle.
• In vivo studies utilized C57BL/6 mice bearing B16 melanoma tumors to measure tumor volume changes.
• Immunofluorescence was employed to analyze CD3, CD8, and PD-L1 expression in tumor tissues from treated and control mice.

Main Results:

• 2-ME significantly inhibited melanoma cell proliferation and migration while inducing apoptosis and altering cell cycle progression in vitro.
• In vivo, 2-ME demonstrated potent anti-tumor activity, reducing tumor volume and increasing the infiltration of CD8+ T cells.
• PD-L1 expression was elevated in 2-ME-treated tumors, suggesting potential synergy with PD-1 blockade.

Conclusions:

• 2-methoxyestradiol (2-ME) effectively suppresses melanoma growth both in vitro and in vivo.
• 2-ME enhances the anti-tumor immune response by increasing CD8+ T cell infiltration.
• 2-ME is a promising candidate for combination therapy with PD-1 blockade to improve melanoma treatment outcomes.